MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control

뉴스 본문을 불러오고 있어요.

MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control | 웨이프 WAPE

MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control

기사 요약

관련 종목

댓글 —